The Efficacy of Nevirapine 400 mg Once Daily in Virologically Suppressed Adult HIV-Infected Patients in Prapokklao Hospital
Article Sidebar
Main Article Content
Abstract
Background: Nevirapine (NVP) is an alternative non-nucleoside reverse transcriptase inhibitor (NNRTI) drug used for the treatment of HIV-infected patients. The standard regimen for NVP is 200 mg twice daily. However, pharmacokinetics studies of NVP have shown that NVP 200 mg twice daily has the same effect as 400 mg once daily. Therefore, NVP could be simplified to a once daily regimen for good compliance.
Objectives: To study the efficacy of NVP 400 mg once daily regimen in adult HIV-infected patients
Materials and methods: In this retrospective study, adult HIV-infected patients who attended the Infectious diseases clinic, Prapokklao Hospital during 2015 were recruited. Patients comprised those virologically suppressed with NVP 200 mg twice daily which was later adjusted to NVP 400 mg once daily. HIV viral load was collected annually until 2018 for evaluation of efficacy.
Results: 517 patients who received NVP 200 mg twice daily with 2 NRTIs and later were adjusted to Tenofovir (TDF) 300 mg once daily, Lamivudine (3TC) 300 mg once daily and Nevirapine (NVP) 400 mg once daily were enrolled. 505 patients (97.7%) had an HIV viral load of less than 200 copies/mL, while 494 patients (95.6%) had an HIV viral load of less than 50 copies/mL.
Conclusion: The modification of NVP 200 mg twice daily to NVP 400 mg once daily demonstrated efficacy for virological control among virologically-suppressed adult HIV-infected patients.
Article Details
References
Department of Disease Control, Ministry of Public Health. Thailand National Guidelines for HIV/AIDS Treatment and Prevention 2017. Nonthaburi: Bureau of AIDS, TB, and STIs; 2017.
Kappelhoff BS, Huitema AD, van Leth F, Robinson PA, MacGregor TR, Lange JM, et al. Pharmacokinetics of nevirapine: once-daily versus twice-daily dosing in the 2NN study. HIV Clinical Trials 2005; 6:254–61.
Van Heeswijk RP, Veldkamp AI, Mulder JW, Meenhorst PL, Wit FW, Lange JM, et al. The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals. AIDS 2000; 14(8): F77-82.
Arasteh K, Ward D, Plettenberg A, Livrozet JM, Orkin C, Cordes C, et al. Twenty-four-week efficacy and safety of switching virologically suppressed HIV-1-infected patients from nevirapine immediate release 200 mg twice daily to nevirapine extended release 400 mg once daily (TRANxITION). HIV Med 2012; 13: 236-44.
Gathe J, Andrade-Villanueva J, Santiago S, Horban A, Nelson M, Cahn P, et al. Efficacy and safety of nevirapine extended-release once daily versus nevirapine immediate-release twice-daily in treatment-naive HIV-1-infected patients. Antivir Ther 2011; 16: 759-69.
Podzamczer D, Olmo M, Sanz J, Boix V, Negredo E, Knobel H, et al. Safety of switching nevirapine twice daily to nevirapine once daily in virologically suppressed patients. J Acquir Immune Defic Syndr 2009; 50: 390-6.